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Abstract
The botulinum neurotoxin serotype A light chain (BoNT/A LC) protease is the catalytic component responsible for the
neuroparalysis that is characteristic of the disease state botulism. Three related peptide-like molecules (PLMs) were
designed using previous information from co-crystal structures, synthesized, and assayed for in vitro inhibition against
BoNT/A LC. Our results indicate these PLMS are competitive inhibitors of the BoNT/A LC protease and their Ki values are in
the nM-range. A co-crystal structure for one of these inhibitors was determined and reveals that the PLM, in accord with the
goals of our design strategy, simultaneously involves both ionic interactions via its P1 residue and hydrophobic contacts by
means of an aromatic group in the P29 position. The PLM adopts a helical conformation similar to previously determined co-
crystal structures of PLMs, although there are also major differences to these other structures such as contacts with specific
BoNT/A LC residues. Our structure further demonstrates the remarkable plasticity of the substrate binding cleft of the BoNT/
A LC protease and provides a paradigm for iterative structure-based design and development of BoNT/A LC inhibitors.
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Introduction
Botulinum neurotoxins (BoNTs), secreted by Clostridium botuli-
num [1], provide invaluable treatments for a range of medical
conditions [2,3,4,5,6,7,8,9,10,11] and cosmetic purposes
[12,13,14,15,16]. Paradoxically, BoNTs are also the most potent
biological toxins known by causing the disease state botulism. As a
result, these enzymes are classified as category A biothreat agents
by the Centers for Disease Control and Prevention (http://
emergency.cdc.gov/agent/agentlist-category.asp), with the clan-
destine contamination of liquids and/or food stuffs being plausible
scenarios [17,18].
The seven known BoNT serotypes are designated A – G. Post
secretion, they undergo proteolytic processing to provide the
bioactive (i.e., poisonous) holotoxin [1]. The holotoxin is
composed of a 100 kDa heavy chain (HC) subunit and a
50 kDa light chain (LC) subunit; these two components are
tethered by a disulfide bridge [1,19,20]. Mechanistically, the HC
binds to specific motor neuron receptors and induces endosomal
internalization [1]. The LC (BoNT/LC) is a zinc (Zn)(II)
metalloprotease that is released from the holotoxin into the
neuronal cytosol [1]. Once inside the neuronal cytosol, the LC
cleaves specific peptide bonds (depending on the serotype) of
proteins composing the neuronal SNARE complex: the synapto-
somal-associated protein of 25 kDa (SNAP-25), the vesicle-
associated membrane protein (VAMP), also referred to as
synaptobrevin, and syntaxin [1,21]. Botulinum neurotoxin sero-
types A, C, and E cleave SNAP-25 [22,23,24]; serotypes B, D, F,
and G cleave VAMP [25,26,27,28], and BoNT serotype C also
cleaves syntaxin [23]. The BoNT/LC mediated proteolytic
cleavage of any one of the three SNARE proteins prevents
acetylcholine-filled vesicles in the neuron from fusing with the
active zone at the synaptic cleft [1]. This inhibits the transmission
of motor nerve impulses, and as indicated above, results in the
flaccid paralysis that is characteristic of botulism [29].
At present, the only treatments available for BoNT intoxication
involve antitoxin administration [1], followed by critical care
mechanical respiration. However, this treatment would not be
practical for treating even a modest number of poisoned
individuals: antitoxin administration is ineffective after BoNT
internalization (and it is likely that victims would seek medical
attention only after the paralysis manifestation). Critical care
mechanical respiration is costly and the small number of medical
facilities in the U.S. equipped with such devices would more than
likely be overwhelmed. Thus, there is an urgent need for the
development of small-molecule inhibitors of BoNT LCs.
Of the seven BoNT serotype LCs, the BoNT serotype A LC
(BoNT/A LC) possesses the longest duration of action in the
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neuronal cytosol [30]. Hence, there continues to be a significant
effort to identify and develop both peptidic and small, drug-like
molecule inhibitors [1] of this particular serotype LC. Previously, we
identified and developed BoNT/A LC inhibitors involving the
simultaneous identification, design, and generation of both small
molecule, non-peptidic, inhibitors (SMNPIs) [29,31,32,33,34] and
peptide-like molecules (PLMs) [35,36]. Such PLM design comple-
ments SMNPI development, as BoNT/A LC:PLM co-crystal
structures form the bases for: 1) the design and synthesis of more
potent, drug-like peptidomimetics, 2) the rational, structure-based
modification of existing SMNPIs to improve inhibitory efficacies,
and 3) the discovery and development of novel SMNPIs via
database mining (employing PLM binding modes as search query
templates). For example, the conformation and chemical contacts of
a PLM bound to the BoNT/A LC can be used to generate three-
dimensional (3D) search queries to discover new SMNPI chemo-
types via the database mining of virtual small molecule libraries.
Here, we describe three new PLMs (Figure 1) that were designed
to explore the BoNT/A LC substrate cleft based on the inhibitor-
protease interactions found in a previously published co-crystal
structure of BoNT/A LC with the inhibitor I1 [35]. The three new
PLMs possess Ki values in the nM range which, together with I1,
place them among the most potent BoNT/A LC inhibitors
characterized to date. One of the PLMs, JTH-NB72-39, was co-
crystallized in complex with the BoNT/A LC protease, confirming
the interactions aimed by our design strategy while revealing new,
unforeseen inhibitor:enzyme contacts that will preface future studies
to design more potent PLM and SMNPI inhibitors.
Results and Discussion
Inhibitor Design
Previously, we reported several nanomolar (nM)-range PLM
inhibitors resembling the cleavage site sequence of SNAP-25 [35].
The seven-residue P1-P69 sequence QRATKML (residue posi-
tions 197–203 of human SNAP-25) was used to design the PLMs.
Of these, a co-crystal structure of the BoNT/A LC with PLM I1
(Figure 1) was determined and its binding contacts and mechanism
of inhibition (with respect to the LC’s active site) were studied in
detail [35]. Based on a general design strategy (Figure 1) and the
BoNT/A LC:I1 co-crystal structure, we attempted to increase the
inhibitory potency of the PLM I1 ‘template’ by replacing and
incorporating different components to increase both ionic and
hydrophobic contacts with residues in the enzymes’s binding cleft,
and to stabilize the 310 helical conformation of I1. We
hypothesized that such conformational stabilization of the
otherwise flexible inhibitor would decrease the binding entropy
of the resulting inhibitors, and thus increase affinity. Along these
lines, we restrained the conformation of I1, as it is bound to the
BoNT/A LC [35], and thus attempted to reduce the inhibitor’s
binding entropy, by introducing an aminoisobutyric acid (Aib)
residue (Figure 1), which is known to favor the type II’ b-turn
repeat in a 310 helix [37,38]. In addition, we replaced the redox-
active DNP-DAP functional group of I1 [35] with an Arg residue,
which, as Kumaran et al. [39,40] demonstrated with co-crystal
structures, provides direct electrostatic contacts with anionic
residues in the BoNT/A LC substrate cleft (in contrast to the
DNP-DAP residue of I1 [35]). Furthermore, we increased the
hydrophobic nature of the C-terminus of I1 by replacing the DAB
residue [35] with an Ala residue (as found in the P49 position of
SNAP-25). Finally, we allowed for combinatorial exploration of
the aromatic hydrophobic interactions of the I1 Trp residue
(Figure 1), mainly by substituting this position with two sterically
and electronically diverse benzyl and naphthylene methylene
substituents. The resulting PLM designs JTH-NB72-35, JTH-
NB72-38, and JTH-NB72-39 are shown in Figure 1.
Inhibitor Synthesis
The synthesis of the PLMs used manual microwave assisted
solid phase peptide synthesis using Fmoc protected amino acids
and Rink amide SS resin. After swelling the resin in dichloro-
methane solvent for 30 min, a stepwise synthesis was initiated by
removal of the Fmoc protecting group from the Rink amide resin
with a solution of 20% piperidine in DMF. The newly formed free
amine was then coupled to the activated, protected amino acid
corresponding to the C-terminus of the desired PLM. Initial
attempts to activate the protected amino acids for coupling using
PyBop and HOBt provided unsatisfactory yields; however, a brief
screening of activating agents revealed that Goodman’s reagent
(DEPBT) provided the desired PLMs in good yield [41,42]. With
the first amino acid successfully coupled to the Rink resin, the
Fmoc group was again removed, and the subsequent, activated,
amino acid was coupled to the freshly deprotected peptide chain.
This process of deprotection and coupling was repeated until the
amide-terminal residue of the desired PLM was appended.
Following the final Fmoc deprotection, the PLMs were cleaved
from the solid support by stirring in a modified version of Reagent
K (87.5% TFA, 3.6% thioanisole, 2.3% EDT, 3.7% phenol, 1.8%
H2O, 1.1% triisopropylsilane) for 2 h at RT. Precipitation with
diethyl ether provided crude products, which were subsequently
purified by preparative RP HPLC (34–42% yield).
In Vitro Inhibition
Using the methods described below, we obtained Ki values in
the nM range for the JTH-NB72-35, JTH-NB72-38, and JTH-
NB72-39 PLMs (Figure 1), although none of them were as potent
as I1. Therefore, co-crystallization experiments were conducted in
order to collect any structural information that might explain this
unexpected result.
Co-crystal Structure of PLM JTH-NB72-39 in complex with
BoNT/A LC
Of the co-crystallization experiments conducted with the three
PLMs, only BoNT/A LC:JTH-NB72-39 produced diffracting
crystals. We obtained a co-crystal structure of this complex at
2.4 A˚ resolution (Table 1). The structure was determined by
molecular replacement using the structure of BoNT/A LC as the
search model (PDB reference code 3DSE [35]), but omitting the
inhibitor coordinates, water molecules, and other ligands (i.e.,
Zn(II) and Ni(II) ions) from the search model[35]. Significant
electron density for the PLM emerged next to the catalytic Zn(II)
around the binding cleft defined by loops 70, 250 and 370 in the
LC protease (Figure 2).
Binding interactions between PLM JTH-NB72-39 and the
BoNT/A LC
The electron density for the first six residues of the PLM
inhibitor is well-defined (i.e., visible at a contour level of 2.0 s in
the Fo-Fc difference electron density map), but is weaker for the
last Leu residue. As discussed in detail below, most of the specific
interactions observed between JTH-NB72-39 and the BoNT/A
LC are mediated by the first four residues of the PLM. Briefly,
JTH-NB72-39 also possesses the electrostatic contacts reported
for the RRGC, RRGI, RRGM, and RRGL tetrapeptides, as well
as for the RRATKM PLM. Moreover, our design resulted in some
of the same hydrophobic interactions previously observed between
I1 and BoNT/A LC [35], but to a lesser degree.
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The carbonyl oxygen of the JTH-NB72-39 P1 residue (Arg)
coordinates the enzyme’s catalytic Zn(II) ion (distance is 2.4 A˚)
and also engages in a hydrogen bond with the hydroxyl group of
residue Tyr 366 (which is known to directly stabilize the
tetrahedral intermediate formed during SNAP-25 catalysis [43]),
while the amino terminal group of the P1 Arg also coordinates the
Figure 1. PLM structures, Ki values, and design strategy. From top to bottom, schematic representation of the SNAP-25 P1-P69 segment, with
the substrate scissile bond indicated in red; representation of the I1 and RRGC PLMs and their corresponding inhibition constants; schematic
representation of the design strategy for the JTH-NB72 PLMs, showing the incorporation of the Arg and the aromatic sidechain (R) in the P1 and the
P29 positions, respectively. The aromatic structures tested in the three JTH-NB72 PLMs are indicated, together with their corresponding Ki values
and standard deviations (these values were calculated as the average of three different measurements).
doi:10.1371/journal.pone.0011378.g001
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enzyme’s catalytic Zn(II) (Figure 2C). Furthermore, the confor-
mation of the backbone atoms of this residue is determined, in
part, by electrostatic interactions between its side-chain and
BoNT/A LC residues. Specifically, and in contrast to I1, the P1
Arg of the inhibitor engages, via a salt bridge, with the LC’s Glu
164 residue while it also shares a hydrogen bond with the carbonyl
oxygen of the LC’s Cys 165 residue (Figures 3A and 4). A similar
ionic contact with Glu 164 has been proposed for Gln 197 in the
P1 position of SNAP-25 substrate during the formation of the
enzyme:substrate complex [44,45]. Moreover, the orientation of
the JTH-NB72-39 P1 Arg resembles that of the P1 Arg residues
found in previously reported tetrameric inhibitors RRGI, RRGC,
RRGM, and RRGL and RRATKM [40] (Figure 3B), but is in
closer contact with the enzyme’s Glu 164, and it is the only PLM
that interacts with Cys 165 of the BoNT/A LC (Figure 4). In
contrast to the binding of the P1 DNP-DAP component of I1 [35],
the JTH-NB72-39 P1 Arg does not interact with BoNT/A LC
residue Ser 259.
In the P19 position of JTH-NB72-39 there is a second Arg
residue (Figure 3). In SNAP-25, a corresponding P19 Arg plays a
key role in facilitating hydrolysis by specifically interacting with
Asp 370 in the S19 pocket[46]. This native interaction is also
exploited by all structurally known peptidic inhibitors, as all
BoNT/A LC:PLM co-crystal structures reported to date posses an
Arg residue at the P19 position which provides optimal binding in
the enzyme’s S19 pocket [35,39,40]. This Arg side chain adopts
one of two rotamers, and both conformations are stabilized by the
formation of a salt bridge with the side-chain carboxylate of
BoNT/A LC residue Asp 370 (Figure 3). The conformation of the
side-chain of the P19 Arg of JTH-NB72-39 closely resembles that
observed for the corresponding P19 Arg residue in PLMs RRGI,
RRGL, and RRATKM [39,40]. Additionally, the guanidinium
group of the P19 Arg engages in a cation-p interaction with
Phe 194 of the LC’s substrate cleft (not shown). This is a contact
that is consistently observed in other BoNT/A LC:PLM
co-crystal structures, and mutations of Phe 194 have been
reported to diminish the catalytic efficiency of the BoNT/A LC
by ,100-fold [47]. Overall, the observed P19-S19 Arg:Asp 370/
Phe 194 interactions appear to be key for general PLM inhibitory
potency.
While looking for additional contacts further down the sequence
of the JTH-NB72-39 PLM, we identified an interaction never
observed before for any other BoNT/A LC inhibitor. The amide
nitrogen of the JTH-NB72-39 P29 Phe residue engages in a water
mediated interaction with the guanidinium group of BoNT/A LC
residue Arg 363 (Figure 5A–C). In other BoNT/A LC:PLM
complexes, such as RRATKM, and those of the tetrameric
peptides RRGI, RRGL, RRGM, and RRGC [39,40], it is the
carbonyl oxygen of the PLM’s P19 that directly interacts with the
enzyme’s Arg 363 side-chain guanidinium group (Figure 5A). For
JTH-NB72-39, this carbonyl group is rotated 180u relative to its
orientation in the tetrameric peptides (Figure 5A). However, by
virtue of this water-mediated interaction with Arg 363, the JTH-
NB72-39 P29 Phe amide nitrogen replaces this direct interaction
observed for other PLMs [39,40]. This is relevant, as the BoNT/A
LC Arg 363 is proposed to be critical for the binding and
hydrolysis of the SNAP-25 substrate, presumably by maintaining
proper geometry and charge distribution around the active site;
mutation of this residue results in a 80-fold decrease of the catalytic
rate of SNAP25 hydrolysis by BoNT/A LC [40,43]. In addition,
the side chain rotamers of Arg 363 are similar for all BoNT/A
LC:PLM complexes, but differ from the rotamer observed in the
unbound form of BoNT/LC, indicating that Arg 363 undergoes
significant conformational changes upon PLM and substrate
binding. This water-mediated contact between the JTH-NB72-
39 and Arg 363 is not observed in the I1-bound BoNT/A LC
complex (Figure 5B).
Another novel interaction observed in this position of the PLM
is a stabilizing, intra-molecular hydrogen bond formed between
the carbonyl oxygen of the P29 Phe and the amide nitrogen of the
P59 Met residues (Figure 5D), which is not present in the I1-bound
complex. There are also hydrophobic interactions between the
aromatic ring of the JTH-NB72-39 P29 Phe and BoNT/A LC
residues previously found to form a hydrophobic pocket for
binding by the larger, indol P29 Trp moiety of I1 [35] (Figure 6).
For JTH-NB72-39, the BoNT/A LC side-chains of Leu 367 and
Phe 369, together with the aliphatic portions of Asn 368,
contribute to the formation of this hydrophobic pocket. Addition-
ally, the aliphatic side-chain of Leu 256 interacts with the JTH-
NB72-39 P29 Phe side-chain (Figure 6), but its electron density is
weaker than observed in the BoNT/A LC:I1 complex, suggesting
that the larger I1 P29 Trp is better suited than the JTH-NB72-39
P29 Phe for stabilizing this residue and forming a non-polar
binding site (Figure 6). This observation partially explains the
lower potency of these three PLMs (Figure 1) relative to I1.
A new PLM component incorporated into the design of JTH-
NB72-39 also present in JTH-NB72-35 and JTH-NB72-38 is
the gem-dimethyl-glycine residue, Aib, in the P39 position (Figure 1).
The rationale for incorporating this component was to stabilize the
PLMs’ observed 310 helical conformation, as inferred from the I1
binding mode [35], and to decrease the binding entropies of the
new designs. In the present co-crystal structure, Aib engages in
favorable intermolecular contacts (via its hydrophobic gem-dimethyl
Table 1. X-ray data collection and refinement.
Space group P21212
a, b, c (A˚) 56.1, 189.6, 41.51
Resolution (A˚) 45–2.4 (2.47–2.4)
Unique reflections 16177
Redundancy 5.5 (5.1)
Completeness (%) 93.3% (77.4%)
I/s 33.8 (5.1)
Rsym (%) 7.1% (32.6%)
Rcryst/Rfree 18.31%/23.08%
No. atoms
BoNT/A LC 3179
JTH-NB72-39 61
Ni 1
Zn 1
Water 117
Average thermal (B) factor
BoNT/A LC 42.30 A˚2
JTH-NB72-39 49.50 A˚2
Ni 43.82 A˚2
Zn 32.14 A˚2
Water 60.4 A˚2
R.m.s. deviations
Average bond length deviation 0.004 A˚
Average bond angle deviation 0.802 u
doi:10.1371/journal.pone.0011378.t001
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groups) with the side-chain of BoNT/A LC residue Val 70, and an
intramolecular, stabilizing, hydrogen bond with the amide nitrogen
of its P69 Leu (not shown). In addition to these interactions, our
structure reveals unexpected conformational restrains introduced
by this Aib residue that affect neighboring residues in the PLM.
The backbone atoms of the more potent I1 PLM superimpose well
with corresponding atoms found in JTH-NB72-39 up to the P29
position (Figure 6B). However, the backbone of JTH-NB72-39
abruptly contracts forming a sharp bend at the P39 position which
results from the distinct conformational effects of the Aib residue.
Based on this observation, we conclude that, in addition to
possessing a smaller volume than the P29 Trp group of I1, and the
concurrent absence of an ionic indol group, the P29 Phe of JTH-
NB72-39 is hindered in its orientation by the geometrical
restraints imposed on the its backbone by the adjacent P39 Aib
residue.
The P49 Ala residue of JTH-NB72-39 engages in intramolec-
ular, hydrophobic interactions with the side-chain methylenes of
the PLM’s P1 Arg and P69 Met, as well as with the backbone
amides of the PLM’s P19 Arg and P39 Aib, while the P59 Met
engages in intermolecular interactions with BoNT/A LC residues
Glu 257, Val 258, Ser 259, and Glu 262, and intra-molecular
contacts with the P1 Arg, P29 Phe, P49 Ala, and P69 Leu. The alkyl
chain of the outermost residue in the inhibitor (i.e., JTH-NB72-
39 P69 Leu), although solvent exposed, engages in favorable
intramolecular interactions with the hydrophobic surfaces of its
neighboring P29 Phe and P39 Aib PLM residues, as well as an
inter-molecular interaction with the BoNT/A LC Phe 369 side-
chain phenyl.
BoNT/A LC substrate binding cleft plasticity
Silvaggi et al. observed structural plasticity in the BoNT/A LC
substrate cleft upon binding to three different hydroxamate
derivatives [48]. This plasticity has also been documented by the
distinct binding contacts identified in subsequent complexes of the
BoNT/A LC with other PLM inhibitors [39,40]. Our co-crystal
structure of JTH-NB72-39 bound to the BoNT/A LC further
underscores this plasticity. Importantly, the complexes of BoNT/A
LC with JTH-NB72-39 and with I1 (PDB reference code 3DS9,
[35]), and the unbound crystal structure (PDB reference code
Figure 2. Initial electron density for the JTH-NB72-39 inhibitor and inhibition of the BoNT/A LC ‘catalytic engine’. A. View of the initial
sA-weighted Fo-Fc difference electron-density map contoured at 2.0 s (grey mesh) around the inhibitor-binding site, and overlaid with the refined
model of the complex (JTH-NB72-39 is depicted in orange sticks, the Zn(II) atom as a yellow sphere, and the BoNT/A LC in cyan ribbon
representation). The map was computed with phases calculated prior to the inclusion of JTH-NB72-39 (i.e. it is a model-bias free map). For the PLM
nitrogen, oxygen, and sulfur atoms are colored blue, red, and yellow, respectively. B. The same as A, but visualized from a different angle. C.
Inhibiting interactions of JTH-NB72-39. BoNT/A LC residues are displayed as cyan sticks, and the JTH-NB72-39 backbone is shown as thin, orange
sticks. Only the P19 Arg side chain of the inhibitor is shown as reference. Interactions between BoNT/A LC and JTH-NB72-39 are represented by
dashed lines. The identity of the residues is indicated. The P1 amino and carbonyl groups are indicated by NH2 and CO, respectively. The C-terminus
of the inhibitor is indicated by the letter C. The Zn(II) atom is represented as a yellow sphere.
doi:10.1371/journal.pone.0011378.g002
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3DSE [35]) crystallized in the same space group with very similar
cell dimensions. Thus, we can make comparisons of conformations
between these specific crystal structures without the potential
influence of crystal packing contacts.
The BoNT/A LC’s overall fold is similar in the bound and
unbound forms: the JTH-NB72-39-bound form superimposes to
the unbound form with a 0.58 A˚ r.m.s.d. for all Ca atoms. In the
BoNT/A LC:JTH-NB72-39 structure, the three LC residues that
directly coordinate the Zn(II) ion in the active site, i.e., His 223, His
227 and Glu 262, maintain the same geometry and conformation
observed in the unbound form of the LC protease. However, Glu
224 no longer associates with the Zn(II) ion via a ‘catalytic water’
Figure 4. Ionic interactions for the P1 residue of PLMs. Close-up views of the P1 Arg residues of PLMs RRGI (purple carbons), RRGL (pink
carbons), RRGM (magenta carbons), RRGC (pale green carbons), RRATKM (tan carbons), and JTH-NB72-39 (orange carbons). BoNT/A LC structures in
complex with the PLM inhibitors indicated above were superposed. BoNT/A LC residues are depicted in larger stick (with cyan carbons and backbone)
and are taken from the coordinates of the BoNT/A LC:JTH-NB72-39 complex. The Zn(II) ion is shown as a yellow sphere. Nitrogen and oxygen atoms
are shown in blue and red, respectively.
doi:10.1371/journal.pone.0011378.g004
Figure 3. The binding of JTH-NB72-39 in the BoNT/A LC substrate cleft. A. Panoramic view of JTH-NB72-39 in the binding cleft of the
BoNT/A LC. JTH-NB72-39 is displayed in orange sticks (for selected residues only) and ribbon representation, with its directionality indicated by its N
and C termini. B. Superposition of RRGI (purple), RRGL (pink), RRGM (magenta), RRGC (green), RRATKM (blue), and I1 (grey) PLM inhibitors in the
binding cleft of the BoNT/A LC. In both panels, selected BoNT/A LC residues are shown in cyan stick and surface representation, and the nitrogen and
oxygen atoms of all inhibitors are colored blue and red, respectively. The coordinates for the BoNT/A LC are those of the JTH-NB72-39-bound (panel
A) and the I1-bound (panel B) complexes. The Zn(II) atom is displayed as a yellow sphere in both panels. Negatively-charged patches in the BoNT/A
LC surface involved in ionic contacts (black dashes) are displayed as red surface.
doi:10.1371/journal.pone.0011378.g003
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molecule, as observed in all crystal structures of the unbound form
of the enzyme; instead it interacts with the amino terminal nitrogen
atom of the PLM via a H-bond (Figure 2C). Additional major
differences between the bound and unbound structures are
observed in the 20, 200, and 250 loops. Specifically, backbone
atom differences observed for the 370 loop suggest JTH-NB72-39-
induced conformational changes around residues Asn 368, Phe 369,
and Asp 370, since similar arrangements of the symmetry mates
near the 370 loop are observed for both bound (JTH-NB72-39 and
I1) and unbound forms of the LC. Residue Phe 369 moves closer to
JTH-NB72-39 than observed for any of the reported tetrameric
peptides or RRATKM [39,40]. This interaction is even more
pronounced in the BoNT/A LC:I1 co-crystal structure. Addition-
ally, I1 is also in closer proximity to BoNT/A LC residue Leu 256
[35] than JTH-NB72-39 (Figure 6). These observations reinforce
the hypothesis that the P29 Trp residue in inhibitor I1 is a more
favorable ‘binding anchor’ than the corresponding P29 Phe of JTH-
NB72-39.
In the unbound form of BoNT/A LC, residues 64–70 adopt a
loop conformation by packing against the b strand formed by
residues 415–420. This loop is unaltered in the I1- and JTH-
NB72-39-bound structures (Figure 7A). However, for the crystal
structures of the complexes with the hydroxamate derivatives and
the CRATKML peptide [49], no electron density was observed
for these residues (Figure 7A). Binding of the tetrapeptides, and of
the QRATKM and RRATKM PLMs results in a significant
displacement of the backbone in the 70 loop away from the active
site (Figure 7B).
Figure 5. Inhibitory interactions of PLMs. Superposition of the structures of the BoNT/A LC complexes with inhibitors JTH-NB72-39 (orange
carbons) and: RRATKM (light blue carbons, panel A), I1 (grey carbons, panel B), and CRATKML (light blue, panel C). BoNT/A LC residues are shown in
cyan stick representation, with oxygen and nitrogen atoms colored red and blue, respectively. The Zn(II) ion and water molecule are displayed as
yellow and blue spheres, respectively. The amino terminal groups of all inhibitors are labeled as NH2. Backbone amide groups in the P29 position of I1
and JTH-NB72-39 are displayed as purple sticks. Dashed lines indicate intermolecular contacts between PLMs and the BoNT/A LC. D. Stick
representation of the P29 Phe and P59 Met residues of the JTH-NB72-39 inhibitor in its bound conformation. The intramolecular H-bond between
the P29 Phe carbonyl and the P59 Met amide groups is indicated as a black dash line. JTH-NB72-39 is displayed with orange carbons and ribbon;
BoNT/A LC secondary structure and surface representation is colored cyan. Nitrogen, carbon, and sulfur atoms are blue, red and yellow, respectively.
The Zn(II) atom is displayed as a yellow sphere.
doi:10.1371/journal.pone.0011378.g005
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Electron density for the 250 loop of the BoNT/A LC is only
observed for structures of the LC complexed with PLMs
containing either no side chain (i.e. a Gly component) or an Ala
in the P29 position (Figure 7C). In contrast, no electron density is
observed for various residues within this loop for either the
unbound form of the BoNT/A LC, or when bound to arginine
hydroxamate (ArgHX) (residues 245–256), I1 (residues 250–253),
or JTH-NB72-39 (residues 247–255) (Figure 7C).
In all BoNT/A LC:inhibitor complexes described thus far,
including the co-crystal described herein, there is a conformational
change in the 367–372 residue segment of the 370 loop that is
associated with rotamer changes in enzyme residues Phe 369 and
Asp 370 (Figure 7D). The latter engages in the salt bridge
(described above) with the Arg sidechain in the P19 position of the
inhibitors, a key specific interaction for binding of the SNAP-25
substrate and substrate-analog inhibitors. As for Phe 369, its side
chain projects away from the binding cleft in the unbound form of
the BoNT/A LC. By contrast, in the JTH-NB72-39 complex, the
center of this ring moves by ,3.5 A˚ towards the binding cleft,
facilitating the formation of a hydrophobic pocket that accom-
modates the Phe aromatic ring of the PLM. This conformational
change for Phe 369 is even more pronounced in the BoNT/A
LC:I1 complex due to this PLM’s larger P29 Trp component
(Figure 7D BoNT/A LC). In all other inhibitor complexes, Phe
369 adopts a conformation that differs when compared with either
the unbound form of the enzyme, the JTH-NB72-39-, or the I1-
bound complexes. Taken together, these conformational changes
observed in the BoNT/A LC protease upon binding with different
inhibitors reveal a highly ‘plastic’ binding cleft.
Conformational helicity and PLM inhibitors of the BoNT/
A LC
Including the present structure, there are now five co-crystal
structures of PLM-based inhibitors in complex with the BoNT/A
LC that are longer than four residues. A common structural feature
found in all five bound PLMs is a 310 helical turn in the inhibitor’s
backbones (Table 2). As indicated above, JTH-NB72-39 was
designed to further stabilize this helical turn by introducing an Aib
residue in the P39 position. Indeed, there is a 310 helical
conformation for the backbone atoms of this PLM, although the
P39 Aib residue slightly distorts the helical turn and deviates from
the canonical 310-helix conformation adopted by I1 (Figure 8A),
likely by virtue of the unusual geometric constrains of this residue,
i.e, the gem-dimethyl effect [50]. The electron density suggests that
the helical pathway also includes the Met residue in the P59 position,
resembling the 310 helix observed for residues P29-P59 in I1.
A helical backbone conformation is also observed in the Zn-
chelating CRATKML PLM[49], similarly encompassing positions
P29 throughout P59 (Figure 8A). Remarkably, only PLMs
containing a Leu in the P69 position adopt a right-handed 310
a-helical conformation, in contrast to two closely related
hexapeptide PLMs lacking a terminal Leu residue (Table 2)
[39]. Instead, the w and y torsion angles for QRATKM and
RRATKM do not correspond to a canonical right-handed helical
conformation (Figure 8B and Table 2). The backbone atoms of
both peptides undergo a geometrical ‘bend’ which is most
conspicuous along the backbone of the Thr residue in QRATKM
(Table 2 and Figure 8B). Whereas inhibitors CRATKML, I1 and
JTH-NB72-39 display a common right handedness (or positive
chirality) of canonical a-helices, the QRATKM and RRATKM
PLMs display unusual negative values in their dihedral a angles
(i.e. negative helical chirality) (Table 2). The helical segments
observed for inhibitors I1, JTH-NB72-39, and CRATKML are
of similar length and entail the same residue positions (i.e. P29-
P59); nevertheless, the CRATKML ‘‘helix’’ is slightly shifted
relative to the other two PLMs due to Zn-coordination by its thiol
group in the P1 Cys. Interestingly, PLMs QRATKM and
RRATKM, which do not adopt a canonical helical conformation,
are less potent (Ki values = 133 mM and 95 mM, respectively) than
the ‘helical’ PLMs JTH-NB72-39, I1, and CRATKML all of
Figure 6. Nonpolar interactions of P29 residues of PLMs. Superposition of the P29 Phe of the JTH-NB72-39 (tan sticks) and the P29 Trp of I1
(grey sticks) in complex with BoNT/A LC. The van der Waals surfaces (dots) of the side-chain atoms of the P29 Phe and P29 Trp illustrate the steric
effect of these aromatic moieties. BoNT/A LC residues are colored cyan and blue for the JTH-NB72-39-bound and the I1-bound models,
respectively. Phe369 and Leu256 of the BoNT/A LC are labeled with their one-letter code and number in the BoNT/A LC sequence, and their side
chains are displayed in stick representation. B. A side view of the interactions shown in Panel A. The backbone atoms of the P39Aib residue of JTH-
NB72-39 are colored orange. The Zn(II) ion is displayed as a yellow sphere in both panels.
doi:10.1371/journal.pone.0011378.g006
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Figure 7. Observed plasticity in the BoNT/A LC substrate binding cleft. Superposition of: A. The 70 loop backbone of BoNT/A LC in the
unbound (tan), I1- (blue), JTH-NB72-39- (cyan), ArgHX- (red), and CRATKML-bound forms (dark green). B. The 70 loop backbone of the BoNT/A LC
in the unbound (tan), I1- (blue), JTH-NB72-39- (cyan), RRGM- (magenta), and RRATKM-bound (orange) forms. C. The 250 loop backbone of the
BoNT/A LC in the unbound (tan), I1- (blue), JTH-NB72-39- (cyan), ArgHX- (red), and QRATKM- bound (grey) forms. D. The 370 loop backbone of the
BoNT/A LC in the unbound (tan), JTH-NB72-39- (red), I1- (blue), and ArgHX-bound (cyan). The backbone is displayed in cartoon representation and
the side chain of BoNT/A LC Phe 369 is shown as sticks.
doi:10.1371/journal.pone.0011378.g007
Table 2. Helicity in BoNT/A LC PLM inhibitors.
Inhibitor
JTH-NB72-39 I1 CRATKML QRATKM RRATKM RRGX*
Position SecStr* a * SecStr a SecStr a SecStr a SecStr a SecStr a
P1 L L L L L L
P19 L L L L 2 L 2 L 2
P29 H + H + H + L 2 L 2 L
P39 H + H + H + S 2 L 2 L
P49 H + H + H + L L
P59 H H H L L
P69 L L L
*Abbreviations:
SecStr: observed secondary structure from pdb coordinates (L: loop; H: Helix; S: Bend).
a: helical chirality (dihedral a angle – positive angle corresponds to a right-handed helix).
RRGX: any of the tetrapeptides reported in [51].
All SS and a values were calculated with the DSSPcont program DSSPcont: Continuous secondary structure assignments for proteins [61].
doi:10.1371/journal.pone.0011378.t002
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which possess nM range Ki values (Table S1). Hence, it is likely
that the P69 Leu residue in the helical PLMs not only stabilizes
their helical conformations, but also increases inhibitory potency
via increased occupation of the enzyme’s substrate binding cleft.
Together with the favorable hydrophobic interactions of the
substituents at the P29 position of JTH-NB72-35, -38, -39, and
I1, the presence of a seventh residue might account for the higher
potency of these PLMs over the hexa- or tetrapeptides reported by
other groups (Table S1) [39,51].
Inhibition mechanism of JTH-NB72-39
The PLM JTH-NB72-39 shares the same inter-molecular
contacts that facilitate the mechanism of inhibition with other
PLMs (Figure 5B), in particular I1, as previously described [35].
Specifically, all PLMs possessing a free amino terminus orient this
substituent such that it engages in contacts with the proton shuttle
Glu 224 side-chain carboxylate (Figure 5A–C). In this way, Glu
224 is no longer capable of ionizing the ‘catalytic’ water molecule
and, as a consequence, it is hampered from using the protons from
this water to catalyze the final cleavage of the scissile bond. In
addition, all reported PLMs exhibit simultaneous, substrate-like
interactions between their P1 residue backbone carbonyl oxygens
and both, the side-chain hydroxyl group of Tyr 366 and the Zn(II)
ion (Figure 5A–C). Furthermore, BoNT/A LC residue Arg 363
engages in electrostatic contacts with the peptidic backbones of
reported PLMs (Figure 5A). The RRGL, RRGI, RRGM, RRGC,
and RRATKM peptides [39,40] consistently contact Arg 363 via
their P19 carbonyl oxygen (Figure 5A). JTH-NB72-39, on the
other hand, forms this interaction indirectly, via a bridging water
molecule (Figure 5A). This difference is most likely due to the
geometric restraints imposed by the aromatic group in the P29
position of JTH-NB72-39 (which is either a Gly or an Ala in all
other PLM inhibitors [39,40]).
The CRATKML inhibitor conformation deviates from those of
all the other PLMs. It is likely that the Zn-coordinating geometry
of the P1 Cys of CRATKML shifts the other interactions in the
complex (Figure 5C) [40]. For its first residue, P1 Cys, the terminal
amino group of this PLM is not proximal to the enzyme’s proton
shuttle - Glu 224, but rather, this P1 Cys engages in contacts with
BoNT/A LC residue Arg 363 through its P1 carbonyl oxygen, as
opposed to the P19 carbonyl oxygen as observed for other PLMs
[39,40] (Figure 5A and 5C). As a result, CRATKML also lacks the
hydrogen bond with Tyr 366 that is detected in all other PLM co-
crystal structures (Figure 5C).
Hypotheses for improving PLM inhibitory efficacies
The PLMs described here were designed in an attempt to
improve potency displayed by previously reported PLM I1 via the
incorporation of a P1 position Arg residue (to engage in direct
electrostatic interactions with BoNT/A LC acidic residues), and
the incorporation of an Aib residue (to stabilize the inhibitors
helical conformations) [35]. However, neither JTH-NB72-35
(Ki = 315.5628.6 nM), JTH-NB72-38 (Ki = 990.56116.9 nM),
nor JTH-NB72-39 (Ki = 638692.0 nM) (Figure 1) are as potent
as I1 (Ki = 41 nM) [35]. The co-crystal structures of JTH-NB72-
39 and I1 in complex with BoNT/A LC explain this surprising
result. The higher Ki value for JTH-NB72-39 compared to I1 is,
in part, due to fewer favorable hydrophobic contacts provided by
the PLM’s Phe component in the P29 position versus the larger P29
Trp of I1. Specifically, the I1 Trp component is more efficient in
coalescing the non-polar side-chains of BoNT/A LC residues Leu
256 and Phe 369 in their common binding site (Figure 6).
Additionally, while the aliphatic side-chain of Leu 256 does
contact the JTH-NB72-39 P29 Phe, the electron density for the
side-chain of this BoNT/A LC residue is weaker than that
observed in the BoNT/A LC:I1 complex [35]. Hence, the I1 P29
Trp residue is more efficient for inducing the formation of this
non-polar pocket than the P29 Phe residue of JTH-NB72-39.
Another unexpected result from our co-crystal structure is that the
Aib residue introduces a slight deformation of the canonical 310
helical backbone conformation observed for I1 (Figure 7A).
Our co-crystal structure also explains the different potencies
observed for the other two PLMs (Figure 1). In particular, the most
potent of the three reported PLMs (i.e., JTH-NB72-35) possesses
a P29 naphthalene methylene substituent, which would more
efficiently bring together, and engage in more favorable
hydrophobic contacts with, the non-polar side-chains of BoNT/
A LC residues Leu 256 and Phe 369 (versus JTH-NB72-39), as
Figure 8. The helical chirality of PLM inhibitors. Superposition of the backbones (tube representation) of all BoNT/A LC PLM inhibitors reported
to date (and which are longer than four residues). A. PLM inhibitors whose backbones display positive helical chirality upon binding to BoNT/A LC:
JTH-NB72-39 (orange), I1 (grey), and CRATKML (blue). B. PLM inhibitors with negative helical chirality upon binding to BoNT/A LC: RRATKM (green),
and QRATKM (red). JTH-NB72-39 (orange) is shown for comparative purposes. The BoNT/A LC Zn(II) ion is shown as a yellow sphere.
doi:10.1371/journal.pone.0011378.g008
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well as with the aliphatic portions of the side-chain of residue Asn
368 at the enzyme binding site. Finally, it is likely that the same
hypothesis applies to JTH-NB72-38; however, while the JTH-
NB72-38 P29 Trp indole does provide a larger ring system for
binding in the indicated BoNT/A LC hydrophobic pocket (see
above), the polar pyrrole nitrogen atom is unable to engage in a
favorable hydrogen bond with the backbone carbonyl of BoNT/A
LC residue Glu 257, an interaction that was previously observed in
the BoNT/A LC:I1 complex (Figure 9A) [35]. Instead, modeling
of a Trp side chain in the P29 position of the JTH-NB72-39 PLM
revealed that none of the rotamers available for the - CH2-indole
side chain positions it so that it engages in a hydrogen bond with
any residue in the enzyme (Figure 9B). Indeed, our analyses
indicated that the polar nature of the JTH-NB72-38 pyrrole
nitrogen results in unfavorable hydrophobic-polar clashes in the
hydrophobic pocket indicated above. Hence, this analysis provides
a rational basis for explaining the higher Ki compared of this PLM
versus those of JTH-NB72-35, JTH-NB72-39, and I1.
The decreased inhibitory efficacies of all three JTH PLMs
compared to Il also appears to be partially due to the fact that they
all incorporate an Arg residue at the P1 versus the P1 – P29 DNP-
DAP component of I1. In particular, the rigidity of the DNP
phenyl and the solvation of its two nitro functional groups may be
necessary for stabilizing this PLM’s helical structure upon binding
in the enzyme’s substrate cleft. This, in turn, would decrease I19s
binding entropy. By comparison, the flexible side-chain of the P1
Arg of the JTH PLMs does not provide the same helix-stabilizing
character. Additionally, the JTH PLMs lack the DAB component
found in I1. In the BoNT/A LC:I1 co-crystal structure, this
cationic component engages in a hydrogen bond with the side-
chain amide of BoNT/A LC residue Gln 162 [35]. Compara-
tively, in the BoNT/A LC:JTH-NB72-39 co-crystal structure, the
PLM’s non-polar P49 Ala residue cannot engage in such a
favorable H-bond. Finally, the initial weak electron density
observed for the C-terminal residues of the JTH PLMs indicates
that these residues may be destabilizing the overall binding modes
of these inhibitors via entropic contributions, and therefore, other
components that engage in more definitive hydrophobic and/or
polar contacts with the enzyme cleft would be necessary for
improving future PLM potencies.
Based on available structural and mechanistic data, future PLM
designs will focus on optimizing the P1 - P29positions, while
simultaneously introducing changes to terminal PLM residues/
components to decrease their entropic contributions. Moreover,
future designs will also incorporate peptidomimetic features that
will increase the drug-like character of the PLMs.
Conclusion
The design and synthesis of three new PLM inhibitors, which
are pivotal for guiding the development of peptidomimetics and
SMNPIs, have been presented. In order to characterize the
binding modes for the PLMs, a co-crystal structure of one, JTH-
NB72-39, was determined, which possesses components that have
been independently reported to directly interact with the active
site of the BoNT/A LC [35,39,40]. Based on comparisons
between the binding mode determined for JTH-NB72-39 with
other non-Zn-chelating BoNT/A LC:PLM co-crystal structures
[35,39,40], a consistent inhibition mechanism has emerged [35].
Specifically, we provide a unifying PLM-based mechanism of
action: in all cases the presence of a P1 amino terminal residue is
key for effectively ‘arresting’ the proteolytic activity of the BoNT/
A LC. This discovery explains why SNAP-25 substrates N-
terminally extended beyond the P1 position are cleaved by the
BoNT/A LC[46]; in such peptides, due to their participation in a
peptide bond with the P2 residue, the P1 amino group becomes an
amide, rendering it non-competent for ‘locking’ the Glu 224
carboxylate group [39]. This observation emphasizes the require-
ment of a highly ionizable group in this position in order to
Figure 9. Modeling of a Trp residue in the P29 position of JTH-NB72-39. A. Cartoon representation of the BoNT/A LC:I1 complex. The BoNT/
A LC is shown in blue, and I1 in dark grey. The dashed line represents an H-bond between the indole nitrogen atom of the P29 Trp and the carbonyl
group of BoNT/A LC residue Glu 257. The H-bond distance is indicated. B. Cartoon representation of the BoNT/A LC:JTH-NB72-39 complex. A Trp
side chain has been modeled in the P29 position (instead of the actual Phe side chain of JTH-NB72-39). The Trp rotamer model shown here
positions the indole nitrogen as can bind in the closest possible proximity to the carbonyl group in Glu 257 (employing the BoNT/A LC: JTH NB72-
39 co-crystal). The solid line indicates the distance (not contact) between these two groups. The BoNT/A LC is shown in cyan, and JTH-NB72-39
carbons and backbone ribbon in orange. The side chains of the P29 Trp in the PLMs and Glu 257 in BoNT/A LC are displayed in stick representation in
both panels. The yellow spheres represent the Zn(II) ion in both panels.
doi:10.1371/journal.pone.0011378.g009
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strongly interact with Glu 224 – to effectively inhibit the BoNT/A
LC protease and will be important for guiding the rational design
of new PLMs and peptidomimetics, as well as for the discovery of
new SMNPIs and the synthetic optimizations of existing SMNPIs.
The JTH-NB72-39-BoNT/A LC co-crystal structure present-
ed here, and its comparison with all other SNAP-25-derived PLM
inhibitor co-crystal structures known to date, highlights the
importance of the BoNT/A LC 370 loop for substrate binding
and cleavage specificity. It is this loop that contains the Asp 370
residue, which is pivotal for substrate discrimination. Also, BoNT/
A LC residue Phe 369 is located in this region, and according to
the structure presented here and the co-crystal structure with I1
[35], forms part of a hydrophobic pocket that efficiently anchors
non-polar groups located in the P29 position of these PLMs.
Future designs will involve PLM components that can further
stabilize a helical backbone orientation without interfering with
binding, as well as the incorporation of bulkier non-polar
components at the P29 position.
Methods
Synthesis
General. N,N-Diisopropylethylamine was sequentially
distilled from ninhydrin then KOH and stored under argon.
Piperidine was distilled from CaH2 and stored under argon.
Phenol was purified by dissolving the solid in diethyl ether,
washing with a saturated aqueous solution of NaHCO3 (3x),
extracting with aqueous NaOH (0.1 M) (3x), acidifying the
aqueous extracts with 0.1 N HCl, extracting with Et2O (3x),
concentrating the ethereal extracts under reduced pressure, and
the dry solid was stored under argon. N,N-Dimethylformamide
was purchased from Alfa Aesar as anhydrous and amine free in
4 L quantities and stored in 1 L Amber bottles (dried overnight in
an oven at 140uC) over activated 4 A˚ molecular sieves under
argon. Trifluoroacetic acid (biochemical grade, 99.5+% pure) was
purchased from Alfa Aesar and used as received. Methanol
(HPLC grade), water (HPLC grade), and thioanisole (99% purity)
were purchased from Aldrich and used as received.
Triisopropylsilane (99% purity) was purchased from Acros and
used as received. 1,2-ethanedithiol (.98% pure) was purchased
from Fluka and used as received. All natural Fmoc-protected
amino acids and 3-(diethoxy-phosphoryloxy)-3H-benzo[d][1,2,3]-
triazin-4-one were purchased from either Peptides International or
Advanced Automated Peptide Protein Technologies (AAPPTEC)
and used as received. Unnatural Fmoc protected amino acids and
Rink Amide Resin SS, 100–200 mesh, 1% DVB were purchased
from Advanced Chemtech and used as received. BD Falcon
BlueMax 50 mL graduated tubes and 25 mm syringe filters with a
0.45 mm nylon frit were purchased from Fischer Scientific.
The Fmoc-solid phase peptide syntheses were performed on a
CEM Discover manual microwave peptide synthesizer fitted with
a fiber-optic temperature probe. Solid phase peptide syntheses
were performed in a 25 mL polypropylene reaction vessel. The
25 mL polypropylene reaction vessel was constructed by inserting
a Teflon ring (0.4 mm height, 2.1 mm outer diameter, 1.8 mm
inner diameter) into a capped 25 mL SPE reservoir purchased
from Grace Davison Discovery Science (Catalogue #: 210425)
containing a frit purchased from Grace Davison Discovery Science
(Catalogue #: 211416) (Figure S1).
Preparative reverse phase HPLC purifications were performed
on a Gilson HPLC system with 220 and 254 nm UV detection,
using a Phenomenex Luna 5m C18(2) 100 A˚, AX (75630.0 mm)
column at a flow rate of 10 mL/min. Unless otherwise noted, all
preparative runs used linear gradients of 30–60% buffer B in A (A:
water containing 0.1% TFA, B: CH3CN containing 0.1% TFA)
over 30 min. Analytical HPLC traces of final products were
performed on a Gilson HPLC system with 220 and 254 nm UV
detection, using a Varian Microsorb 100-3 C18 (10064.6 mm)
column at a flow rate of 0.7 mL/min. Unless otherwise noted, all
analytical runs used linear gradients of 30–100% buffer B in A (A:
water containing 0.1% TFA, B: MeOH) over 70 min. CD Spectra
were recorded on a Jasco J-815 Circular Dichroism Spectrometer.
Unless otherwise noted, all CD spectra were recorded in MeOH at
a concentration of 0.5 mM, at 298 K, over a range of 300–
200 nm, at a scan rate of 50 nm/min. Mass spectra were obtained
using MALDI TOF/TOF with 2,5-dihydroxybenzoic acid as the
matrix in the positive ion mode. Lyophilization was accomplished
using a Labconco FreeZone 4.5 liter bench top freeze dry system.
Centrifugation was accomplished using a Sorvall RT-7 Plus bench
top centrifuge.
Proton and carbon NMR spectra were recorded using a Bruker
Avance spectrometer at 600 MHz/150 MHz (1H NMR/13C
NMR) in D2O (298 K), unless otherwise noted. Chemical shifts
(d) are reported in parts per million (ppm) using MeOH solvent
peaks as an internal reference (referenced to 3.34 ppm (1H) and
49.5 ppm (13C)). 1H NMR data are reported as follows: chemical
shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet,
m = multiplet, dd = doublet of doublets, dt = doublet of triplets,
td = triplet of doublets, qd = quartet of doublets), coupling
constants (J) in Hertz (Hz), and integration. 13C NMR spectra
were obtained using a proton-decoupled pulse sequence with d1 of
6 sec, and are tabulated by observed peak.
A stock solution of the coupling base was prepared by dissolving
DIPEA (1.74 mL, 1.00 mmol) in DMF (5.00 mL) to give a
0.148 M solution. A stock solution of the Fmoc-cleavage base was
prepared by dissolving piperidine (1.00 mL, 10.1 mmol) in DMF
(4.00 mL) to give a 2.02 M solution. A stock solution of the resin
cleavage cocktail was prepared by combining TFA (5.07 g,
44.5 mmol), PhSCH3 (0.210 g, 1.69 mmol), PhOH (0.215 g,
2.28 mmol), TIPSH (0.0620 g, 0.392 mmol), 1,2-EDT (0.135 g,
1.43 mmol) and H2O (0.100 g, 5.56 mmol). All stock solutions
were freshly prepared prior to use.
General procedure A: solid phase peptide synthesis. To
a 25 mL polypropylene reaction vessel charged with a Teflon stir
bar (1063 mm) was added the Rink Amide resin (0.143 g,
0.100 mmol, loading 0.700 mmol/g, 1.00 equiv). The resin was
washed with MeOH (265 mL), CH2Cl2 (3610 mL) and DMF
(3610 mL), suspended in CH2Cl2 (5 mL) and allowed to swell at
room temperature for 30 min. The resin was filtered and washed
with DMF (3610 mL). The Fmoc group was cleaved by heating
the resin in the Fmoc-cleavage base stock solution (1 mL) in the
microwave (35 W, 78uC, 3 min). The resin was filtered and
washed with DMF (3610 mL), CH2Cl2 (3610 mL) and DMF
(3610 mL). The first Fmoc protected amino acid was coupled to
the resin by heating in a pre-mixed solution of amino acid
(0.350 mmol, 3.50 equiv), DEPBT (0.105 g, 0.350 mmol, 3.50
equiv), DMF (0.80 mL), and Fmoc-coupling base stock solution
(0.75 mL) in the microwave (25 W, 80uC, 5 min). The resin was
filtered and washed with DMF (3610 mL), CH2Cl2 (3610 mL)
and DMF (3610 mL). The Fmoc group was cleaved as previously
described, and the next amino acid was coupled. This process of
Fmoc cleavage and amino acid coupling was repeated for each
additional amino acid. After the final Fmoc cleavage, the resin was
washed with DMF (30 mL) and CH2Cl2 (20 mL). The protecting
groups were cleaved by treatment of the dry resin with the resin
cleavage cocktail stock solution (2.50 mL) for 2 h at room
temperature with vigorous stirring. The resin was filtered and
rinsed with the remaining resin cleavage cocktail stock solution
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(1.50 mL) and TFA (1.50 mL), collecting the filtrate and rinses in
a 50 mL BD Falcon tube. The sample was concentrated to a
heterogeneous mixture (approximately 0.2 mL) under a stream of
argon for 30 min. Cold diethyl ether (45 mL) was added to
precipitate the crude peptide. The sample was centrifuged
(3200 rpm, 28uC, 15 min) and the supernatant was discarded.
The crude peptide was transferred to a 20 mL scintillation vial
with approximately 5 mL of a mixture of H2O/CH3CN (9:1) and
lyophilized overnight. The crude peptide was dissolved in H2O
containing 0.1% TFA (5.00 mL) and filtered through a 0.45 mm
nylon syringe filter. The filtrate was purified by preparative RP
HPLC.
JTH-NB72-35 synthesis. Prepared according to general
procedure A utilizing the following amino acid sequence: Fmoc-
L-Leu-OH (0.124 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Met-OH
(0.130 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Ala-OH (0.115 g,
0.350 mmol, 3.50 equiv), Fmoc-Aib-OH (0.114 g, 0.350 mmol,
3.50 equiv), Fmoc-L-1-Nal-OH (0.153 g, 0.350 mmol, 3.50
equiv), Fmoc-L-Arg(Pbf)-OH (0.227 g, 0.350 mmol, 3.50 equiv),
Fmoc-L-Arg(Pbf)-OH (0.227 g, 0.350 mmol, 3.50 equiv). JTH-
NB72-35 (0.0399 g, 40%) was obtained as a white powder: The
product was characterized by 1H NMR (Table S2); 13C NMR
(Table S2); DEPT-135; COSY; HMBC; HMQC; HPLC RT
5.7 min, HRMS (MALDI+) m/z calcd for C43H71N14O7S [M+H]
927.5351, Found 927.5355. Figures S2 and S3 provide the CD
spectrum and HPLC trace, respectively, for this PLM.
JTH-NB72-38 synthesis. Prepared according to general
procedure A utilizing the following amino acid sequence: Fmoc-
L-Leu-OH (0.124 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Met-OH
(0.130 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Ala-OH (0.115 g,
0.350 mmol, 3.50 equiv), Fmoc-Aib-OH (0.114 g, 0.350 mmol,
3.50 equiv), Fmoc-L-Trp(Boc)-OH (0.185 g, 0.350 mmol, 3.50
equiv), Fmoc-L-Arg(Pbf)-OH (0.227 g, 0.350 mmol, 3.50 equiv),
Fmoc-L-Arg(Pbf)-OH (0.227 g, 0.350 mmol, 3.50 equiv). JTH-
NB72-38 (0.0415 g, 41%) was obtained as a white powder: The
product was characterized by 1H NMR (Table S3); 13C NMR
(Table S3); DEPT-135; COSY; HMBC; HMQC; HPLC RT
5.7 min, HRMS (MALDI+) m/z calcd for C41H70N15O7S [M+H]
916.5303, Found 916.5461. Figures S4 and S5 provide the CD
spectrum and HPLC trace, respectively, for this PLM.
JTH-NB72-39 synthesis. Prepared according to general
procedure A utilizing the following amino acid sequence: Fmoc-
L-Leu-OH (0.124 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Met-OH
(0.130 g, 0.350 mmol, 3.50 equiv), Fmoc-L-Ala-OH (0.115 g,
0.350 mmol, 3.50 equiv), Fmoc-Aib-OH (0.114 g, 0.350 mmol,
3.50 equiv), Fmoc-L-Phe-OH (0.136 g, 0.350 mmol, 3.50 equiv),
Fmoc-L-Arg(Pbf)-OH (0.227 g, 0.350 mmol, 3.50 equiv), Fmoc-L-
Arg(Pbf)-OH (0.227 g, 0.350 mmol, 3.50 equiv). JTH-NB72-39
(0.0318 g, 34%) was obtained as a white powder: The product was
characterized by 1H NMR (Table S4); 13C NMR (Table S4);
DEPT-135; COSY; HMBC; HMQC; HPLC RT 5.6 min,
HRMS (MALDI+) m/z calcd for C39H68N14NaO7S [M+Na]
899.5014, Found 899.5021. Figures S6 and S7 provide the CD
spectrum and HPLC trace, respectively, for this PLM.
In vitro testing
The HPLC-based assay used to calculate PLM inhibition
constants has been published extensively [46,52,53,54,55,56]. In
brief, the assay utilizes an N-terminal acetylated, C-terminal
aminated, synthetic peptide identical in sequence to residues 187–
203 of SNAP-25. Substrate hydrolysis is determined by HPLC
separation of the products from the substrate, followed by
measurement of the peak areas. Assay mixtures consisted of
40 mM HEPES–0.05% Tween (pH 7.3), recombinant BoNT/A
LC, peptide substrate, 0.5 mg/ml Bovine Serum Albumin, and
various PLM concentrations. Assays were run at 37uC, quenched
by the addition of TFA, and analyzed by reverse-phase HPLC. To
eliminate Zn chelating agents, the assay is run in the presence of
excess Zn (50 mM). Ki values were calculated by measuring PLM
mediated inhibition at different substrate concentrations and
treating the kinetic data by the method of Dixon. Inhibition
constants (i.e. Ki values) were extracted from the slopes of Dixon
plots: Ki = Km/(slope x Vmax x S), where S is the substrate
concentration. All reported values are averages of at least three
independent determinations using nine PLM concentrations.
X-ray crystallography and structural analysis
BoNT/A LC: PLMs mixture preparation. Details of the
bacterial expression and purification of the active form of wt
BoNT/A LC used in this study have been previously
described[45]. Stock solutions of wt BoNTA-LC containing
20 mM HEPES, pH 7.4 were adjusted to a final 150 mM
protein concentration. Lyophilized JTH-NB72-35, -38, and -
39 inhibitors were resuspended in distilled water to a final 10 mM
concentration. Individual mixtures of BoNT/A LC and each of
the three PLMs were prepared by mixing both stock solutions to
attain a final 50 mM BoNT/A LC and 1 mM PLM
concentrations.
Crystallization and data collection. Crystals were obtained
by using the hanging drop vapor diffusion method at 20uC.
Briefly, 3 mL of a mixture of 50 mM BoNT/A and 1 mM of each
PLM inhibitor were mixed with 1.5 mL of the mother liquor
containing 14% PEG MME 2000, 10 mM NiCl2, and 100 mM
HEPES pH 8.5. A layer of a 1:1 mixture of paraffin:silicon oil was
overlaid onto the mother liquor present in the well. Crystals for the
BoNT/A LC:JTH-NB72-39 mixture appeared after
approximately five days of incubation and they were directly
transferred into a cryo-solution containing 25%(v/v) PEG600,
0.14 X PEG MME 2000, 10 mM NiCl2, and 100 mM HEPES
pH 8.5, and then flash-frozen in liquid nitrogen. Only
microcrystals were observed for the other two PLMs, and
further manipulation did not result in any improvement of their
size. The diffraction data were collected at beamline 11.1 of the
SSRL (Stanford Synchrotron Radiation Laboratory) at a
wavelength of 1 A˚, and at a temperature of 100 uK. The
diffracted crystals belonged to the P21212 group. Integration,
indexing, and scaling of the diffraction data was performed using
the HKL2000 suite of programs [57].
Structure determination and refinement of the wt BoNT/
A LC:JTH-NB72-39 complex. The coordinates in the 1XTF
pdb file were used as the search model to determine the structure of
the wt BoNT/A LC:JTH-NB72-39 complex by molecular
replacement using the PHASER module in CCP4i [58]. The
initial values for the Rwork and Rfree of the generated model were
27.1% and 31.3%, respectively. The sA-weighted mFo-Fc electron
density map clearly indicated the presence of JTH-NB72-39 in the
vicinity of the active site (Fig. 2). The coordinates of the JTH-NB72-
39 inhibitor were then added to those of the BoNT/A LC in the
structure of the complex using Coot[59]. Final refinement and
modeling was performed using Phenix [60]. The quality of the final
structure was assessed using MolProbity. Ramachandran analysis
showed that the BoNT/A LC:JTH-NB72-39 structure had 97.14%
residues in the favored region with no outliers. The coordinates and
structure factors have been deposited in the PDB (ID 3NF3).
Analysis of the secondary structure of PLM inhibitors
In order to determine the secondary structure of all the PLM
inhibitors reported to date, the pdb files for their complexes with
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BoNT/A LC were used as input for the DSSPcont program [61].
The output of this analysis was used to build Table 2.
Supporting Information
Figure S1 Diagram of assembled 25 mL polypropylene reaction
vessel.
Found at: doi:10.1371/journal.pone.0011378.s001 (0.11 MB
DOC)
Figure S2 CD spectrum of JTH-NB72-35 (0.5 mmol) in
MeOH.
Found at: doi:10.1371/journal.pone.0011378.s002 (0.38 MB
DOC)
Figure S3 Analytical HPLC trace of JTH-NB72-35 using a
linear gradient of 30–100% buffer B in A (A: water containing
0.1% TFA, B: MeOH) over 70 min with UV detection at 220 nm.
Found at: doi:10.1371/journal.pone.0011378.s003 (0.14 MB
DOC)
Figure S4 CD spectrum of JTH-NB72-38 (0.5 mmol) in
MeOH.
Found at: doi:10.1371/journal.pone.0011378.s004 (0.37 MB
DOC)
Figure S5 Analytical HPLC trace of JTH-NB72-38 using a
linear gradient of 30–100% buffer B in A (A: water containing
0.1% TFA, B: MeOH) over 70 min with UV detection at 220 nm
at a flow rate of 0.7 mL/min.
Found at: doi:10.1371/journal.pone.0011378.s005 (0.14 MB
DOC)
Figure S6 CD spectrum of JTH-NB72-39 (0.5 mmol) in
MeOH.
Found at: doi:10.1371/journal.pone.0011378.s006 (0.37 MB
DOC)
Figure S7 Analytical HPLC trace of JTH-NB72-39 using a
linear gradient of 30–100% buffer B in A (A: water containing
0.1% TFA, B: MeOH) over 70 min with UV detection at 220 nm
at a flow rate of 0.7 mL/min.
Found at: doi:10.1371/journal.pone.0011378.s007 (0.14 MB
DOC)
Table S1 Potencies of structurally characterized BoNT/A LC
inhibitors.
Found at: doi:10.1371/journal.pone.0011378.s008 (0.07 MB
DOC)
Table S2 1H and 13C NMR Data for JTH-NB72-35 (Figure 1)
(600 MHz/150 MHz) in D2O (298 K) with MeOH as an internal
reference (referenced to 3.34 ppm (1H) and 49.5 ppm (13C)).
Found at: doi:10.1371/journal.pone.0011378.s009 (0.13 MB
DOC)
Table S3 1H and 13C NMR Data for JTH-NB72-38 (Figure1)
(600 MHz/150 MHz) in D2O (298 K) with MeOH as an internal
reference (referenced to 3.34 ppm (1H) and 49.5 ppm (13C)).
Found at: doi:10.1371/journal.pone.0011378.s010 (0.14 MB
DOC)
Table S4 1H and 13C NMR Data for JTH-NB72-39 (Figure1)
(600 MHz/150 MHz) in D2O (298 K) with MeOH as an internal
reference (referenced to 3.34 ppm (1H) and 49.5 ppm (13C)).
Found at: doi:10.1371/journal.pone.0011378.s011 (0.08 MB
DOC)
Acknowledgments
We thank Dr. Yuan-Ping Pang for his useful comments on the geometry of
the Zn(II) coordination, and Dr. Tim Fenn for discussions.
Author Contributions
Conceived and designed the experiments: JEZ JEN JCB PW SB ATB.
Performed the experiments: JEZ JTH PW. Analyzed the data: JEZ JTH
OD JCB RG PW ATB. Contributed reagents/materials/analysis tools:
JTH JEN RG. Wrote the paper: JEZ OD JCB PW SB ATB.
References
1. Willis B, Eubanks LM, Dickerson TJ, Janda KD (2008) The strange case of the
botulinum neurotoxin: using chemistry and biology to modulate the most deadly
poison. Angew Chem Int Ed Engl 47: 8360–8379.
2. Albanese A, Bentivoglio AR, Cassetta E, Viggiano A, Maria G, et al. (1995)
Review article: the use of botulinum toxin in the alimentary tract. Aliment
Pharmacol Ther 9: 599–604.
3. Bhidayasiri R, Truong DD (2005) Expanding use of botulinum toxin. J Neurol
Sci 235: 1–9.
4. Caya JG, Agni R, Miller JE (2004) Clostridium botulinum and the clinical
laboratorian: a detailed review of botulism, including biological warfare
ramifications of botulinum toxin. Arch Pathol Lab Med 128: 653–662.
5. Cheng CM, Chen JS, Patel RP (2006) Unlabeled uses of botulinum toxins: a
review, part 1. Am J Health Syst Pharm 63: 145–152.
6. Cheng CM, Chen JS, Patel RP (2006) Unlabeled uses of botulinum toxins: a
review, part 2. Am J Health Syst Pharm 63: 225–232.
7. Foster KA (2005) A new wrinkle on pain relief: re-engineering clostridial
neurotoxins for analgesics. Drug Discov Today 10: 563–569.
8. Foster KA (2004) The analgesic potential of clostridial neurotoxin derivatives.
Expert Opin Investig Drugs 13: 1437–1443.
9. Gui D, Cassetta E, Anastasio G, Bentivoglio AR, Maria G, et al. (1994)
Botulinum toxin for chronic anal fissure. Lancet 344: 1127–1128.
10. Gui D, Rossi S, Runfola M, Magalini SC (2003) Review article: botulinum toxin
in the therapy of gastrointestinal motility disorders. Aliment Pharmacol Ther 18:
1–16.
11. Shapiro RL, Hatheway C, Swerdlow DL (1998) Botulism in the United States: a
clinical and epidemiologic review. Ann Intern Med 129: 221–228.
12. Glogau RG (2002) Review of the use of botulinum toxin for hyperhidrosis and
cosmetic purposes. Clin J Pain 18: S191–197.
13. Glogau RG (1998) Botulinum A neurotoxin for axillary hyperhidrosis. No sweat
Botox. Dermatol Surg 24: 817–819.
14. Lipozencic J, Bukvic Mokos Z (2006) Cosmetic dermatology - where is it today?
Acta Dermatovenerol Croat 14: 60.
15. Sposito MM (2002) New indications for botulinum toxin type A in treating facial
wrinkles of the mouth and neck. Aesthetic Plast Surg 26: 89–98.
16. Sposito MM (2002) New indications for botulinum toxin type a in cosmetics:
mouth and neck. Plast Reconstr Surg 110: 601-611; discussion 612–603.
17. Wein LM, Liu Y (2005) Analyzing a bioterror attack on the food supply: the case
of botulinum toxin in milk. Proc Natl Acad Sci U S A 102: 9984–9989.
18. Paddle BM (2003) Therapy and prophylaxis of inhaled biological toxins. J Appl
Toxicol 23: 139–170.
19. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC (1998) Crystal
structure of botulinum neurotoxin type A and implications for toxicity. Nat
Struct Biol 5: 898–902.
20. Turton K, Chaddock JA, Acharya KR (2002) Botulinum and tetanus
neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci
27: 552–558.
21. Singh BR (2000) Intimate details of the most poisonous poison. Nat Struct Biol
7: 617–619.
22. Binz T, Blasi J, Yamasaki S, Baumeister A, Link E, et al. (1994) Proteolysis of
SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem 269: 1617–1620.
23. Blasi J, Chapman ER, Yamasaki S, Binz T, Niemann H, et al. (1993) Botulinum
neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/
syntaxin. Embo J 12: 4821–4828.
24. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, et al. (1993) Botulinum
neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365: 160–163.
25. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, et al.
(1992) Tetanus and botulinum-B neurotoxins block neurotransmitter release by
proteolytic cleavage of synaptobrevin. Nature 359: 832–835.
26. Schiavo G, Malizio C, Trimble WS, Polverino de Laureto P, Milan G, et al.
(1994) Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-
Ala peptide bond. J Biol Chem 269: 20213–20216.
27. Schiavo G, Rossetto O, Catsicas S, Polverino de Laureto P, DasGupta BR, et al.
(1993) Identification of the nerve terminal targets of botulinum neurotoxin
serotypes A, D, and E. J Biol Chem 268: 23784–23787.
Botulinum Neurotoxin Inhibitor
PLoS ONE | www.plosone.org 14 June 2010 | Volume 5 | Issue 6 | e11378
28. Schiavo G, Shone CC, Rossetto O, Alexander FC, Montecucco C (1993)
Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/
synaptobrevin. J Biol Chem 268: 11516–11519.
29. Hermone AR, Burnett JC, Nuss JE, Tressler LE, Nguyen TL, et al. (2008)
Three-dimensional database mining identifies a unique chemotype that unites
structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone
pharmacophore. ChemMedChem 3: 1905–1912.
30. Keller JE (2006) Recovery from botulinum neurotoxin poisoning in vivo.
Neuroscience 139: 629–637.
31. Burnett JC, Opsenica D, Sriraghavan K, Panchal RG, Ruthel G, et al. (2007) A
refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based
inhibitors of the botulinum neurotoxin serotype A metalloprotease. J Med
Chem 50: 2127–2136.
32. Burnett JC, Ruthel G, Stegmann CM, Panchal RG, Nguyen TL, et al. (2007)
Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide
binding mode to a small molecule that is active in primary neurons. J Biol Chem
282: 5004–5014.
33. Burnett JC, Schmidt JJ, Stafford RG, Panchal RG, Nguyen TL, et al. (2003)
Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease
activity. Biochem Biophys Res Commun 310: 84–93.
34. Wang CB, Widom J, Petronijevic F, Burnett JC, Nuss JE, et al. (2009) Synthesis
and Biological Evaluation of Inhibitors of Botulinum Neurotoxin Metallopro-
tease. Heterocycles 79: 487–520.
35. Zuniga JE, Schmidt JJ, Fenn T, Burnett JC, Arac D, et al. (2008) A potent
peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very
different conformation than SNAP-25 substrate. Structure 16: 1588–1597.
36. Wipf P, Xiao JB, Stephenson CRJ (2009) Peptide-Like Molecules (PLMs): A
Journey from Peptide Bond Isosteres to Gramicidin S Mimetics and
Mitochondrial Targeting Agents. Chimia 63: 764–775.
37. Wipf P, Kunz RW, Prewo R, Heimgartner H (1988) Conformational analysis of
tripeptide models: The influence of a, a-disubstituted a-amino acids on
secondary structure. Part II. X-ray analysis and conformational energy
calculations. helv chim acta 71: 268–273.
38. Wipf P, Heimgartner H (1988) Conformational analysis of tripeptide models:
The influence of a, a-disubstituted a-amino acids on secondary structure. Part I.
NMR and CD Investigations. helv chim acta 71: 258–267.
39. Kumaran D, Rawat R, Ahmed SA, Swaminathan S (2008) Substrate binding
mode and its implication on drug design for botulinum neurotoxin A. PLoS
Pathog 4: e1000165.
40. Kumaran D, Rawat R, Ludivico ML, Ahmed SA, Swaminathan S (2008)
Structure- and substrate-based inhibitor design for Clostridium botulinum
neurotoxin serotype A. J Biol Chem 283: 18883–18891.
41. Li H, Jiang X, Ye YH, Fan C, Romoff T, et al. (1999) 3-(Diethoxypho-
sphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT): a new coupling reagent
with remarkable resistance to racemization. Org Lett 1: 91–93.
42. Ye YH, Li H, Jiang X (2005) DEPBT as an efficient coupling reagent for amide
bond formation with remarkable resistance to racemization. Biopolymers 80:
172–178.
43. Binz T, Bade S, Rummel A, Kollewe A, Alves J (2002) Arg(362) and Tyr(365) of
the botulinum neurotoxin type a light chain are involved in transition state
stabilization. Biochemistry 41: 1717–1723.
44. Breidenbach MA, Brunger AT (2005) New insights into clostridial neurotoxin-
SNARE interactions. Trends Mol Med 11: 377–381.
45. Breidenbach MA, Brunger AT (2004) Substrate recognition strategy for
botulinum neurotoxin serotype A. Nature 432: 925–929.
46. Schmidt JJ, Stafford RG, Bostian KA (1998) Type A botulinum neurotoxin
proteolytic activity: development of competitive inhibitors and implications for
substrate specificity at the S19 binding subsite. FEBS Lett 435: 61–64.
47. Chen S, Kim JJ, Barbieri JT (2007) Mechanism of substrate recognition by
botulinum neurotoxin serotype A. J Biol Chem 282: 9621–9627.
48. Silvaggi NR, Boldt GE, Hixon MS, Kennedy JP, Tzipori S, et al. (2007)
Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain
complexed with small-molecule inhibitors highlight active-site flexibility. Chem
Biol 14: 533–542.
49. Silvaggi NR, Wilson D, Tzipori S, Allen KN (2008) Catalytic features of the
botulinum neurotoxin A light chain revealed by high resolution structure of an
inhibitory peptide complex. Biochemistry 47: 5736–5745.
50. Bachrach SM (2008) The gem-dimethyl effect revisited. J Org Chem 73:
2466–2468.
51. Kumaran D, Rawat R, Ludivico ML, Ahmed SA, Swaminathan S (2008)
Structure and substrate based inhibitor design for clostridium botulinum
neurotoxin serotype A. J Biol Chem.
52. Schmidt JJ, Bostian KA (1997) Endoproteinase activity of type A botulinum
neurotoxin: substrate requirements and activation by serum albumin. J Protein
Chem 16: 19–26.
53. Schmidt JJ, Bostian KA (1995) Proteolysis of synthetic peptides by type A
botulinum neurotoxin. J Protein Chem 14: 703–708.
54. Schmidt JJ, Stafford RG (2003) Fluorigenic substrates for the protease activities
of botulinum neurotoxins, serotypes A, B, and F. Appl Environ Microbiol 69:
297–303.
55. Schmidt JJ, Stafford RG (2002) A high-affinity competitive inhibitor of type A
botulinum neurotoxin protease activity. FEBS Lett 532: 423–426.
56. Schmidt JJ, Stafford RG, Millard CB (2001) High-throughput assays for
botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F. Anal
Biochem 296: 130–137.
57. Otwinowski Z, Minor W (1997) Processing of X-ray Diffraction Data Collected
in Oscillation Mode. Meth Enz 276: 307–326.
58. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ (2005) Likelihood-
enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 61:
458–464.
59. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics.
Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
60. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, et al.
(2002) PHENIX: building new software for automated crystallographic structure
determination. Acta Crystallogr D Biol Crystallogr 58: 1948–1954.
61. Carter P, Andersen CA, Rost B (2003) DSSPcont: Continuous secondary
structure assignments for proteins. Nucleic Acids Res 31: 3293–3295.
Botulinum Neurotoxin Inhibitor
PLoS ONE | www.plosone.org 15 June 2010 | Volume 5 | Issue 6 | e11378
